Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) shares climbed after its melanoma immunotherapy iSCIB1+ showed a 69% response rate in a Phase II trial. That’s well above the typical 50% seen with standard care alone.
IXICO PLC (LSE:IXI, OTC:PHYOF) is boosting its Alzheimer’s work through a new deal with the Global Alzheimer’s Platform, gaining full access to key biomarker data. The partnership supports its push into blood-based diagnostics and vascular imaging.
Solvonis Therapeutics PLC (LSE:SVNS) has started regulatory studies in the US for its lead alcohol addiction treatment, SVN‑002, a sublingual esketamine film. It’s aiming for a faster FDA approval path using existing Spravato data.
hVIVO PLC (AIM:HVO) confirmed it’s trading as expected, with first-half revenue hitting £24.2 million. While margins have narrowed, a big sales pipeline is building, including what could be its largest ever contracts.
Thor Explorations Ltd (TSX-V:THX, AIM:THX, OTC:THXPF) reported solid early drilling results from the Guitry gold project in Côte d'Ivoire, confirming gold at surface and deeper levels. High grades include 10 metres at 10.36 grams per tonne.
Oriole Resources PLC (AIM:ORR) has extended gold mineralisation at its Mbe project in Cameroon to at least 300 metres. Over 250 gold intersections have now been logged, with a maiden resource due in Q4 2025.
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.
